Changing the EU Public Health Dynamic: Better science, regulation and access policies to deliver biopharmaceutical innovation for Europe’s citizen
Atlanta, Georgia (US), 20 May 2009
Better science, better regulation and better access policies are needed in Europe to support an innovative healthcare industry and the bio-pharmaceutical industry to deliver state-of-the-art standards of prevention, treatment and cures for EU citizens.
This was today the plea to policy-makers by EuropaBio which organised a major event at the BIO Convention in Atlanta. During the session entitled Europe: The Changing Dynamics of the Public Health Environment Thomas Lonngren, Executive Director at the European Medicines Agency (EMEA), Giulia Del Brenna, Head of Unit, competitiveness in the pharmaceuticals industry and biotechnology at the European Commission, Directorate General Enterprise and Industry, and Francois Meyer, Head of HTA at Haute Authorite de Sante (HAS) and member of the EUnetHTA network, discussed ways to improve the EU decision making process to allow direct involvement, for stakeholders, increased public consultation and more co-decision between institutional actors.
EuropaBio reiterated its call for further and better regulation, involving all EU stakeholder groups, to ensure that patients are at the centre of public health policies to effectively answer society’s unmet healthcare needs.
“In the weeks to come, the EU will welcome a new European Parliament and a new European Commission. We are calling on them to ensure that there will be even stronger dialogue between policy-makers, regulators, HTA bodies and relevant stakeholders to ensure that patients’ interests are at the heart of every healthcare policy and legislation in Europe,” says Andrea Rappagliosi, Chair of the Healthcare Council at EuropaBio. He added: “To secure timely and equal public access to safe, high quality and efficient bio-pharmaceutical products, we urge the setting up of coordinated political and regulatory measures in healthcare, from prevention to treatment. This will ensure that patients and citizens receive the most innovative healthcare solutions available, and that payers secure value for the investments they make.”
Following the success of its session at the BIO Convention and guided by the principles of its Healthcare Manifesto (1), EuropaBio will continue to work hand-in-hand with EU policy-makers, regulators, patients’ advocacy groups and all healthcare stakeholders to ensure that EU healthcare systems in Europe are patient-centred.
Notes to the Editor
EuropaBio is the European Association for Bioindustries, solely and uniquely bringing together bioscience companies from all fields of research and development, testing, manufacturing and distribution of biotechnology products. It has 68 corporate and 7 associated members, 4 BioRegions and 25 national biotechnology associations representing some 1800 small and medium sized enterprises involved in research
(1) EuropaBio’s Healthcare Manifesto 2009-2010
EuropaBio’s Healthcare Manifesto is the Healthcare Council’s Political Road Map for 2009 and 2010 for how to deliver a patient–centred approach to modern healthcare. The Healthcare Manifesto is available here.
For further information, please contact
Director Healthcare Biotech, EuropaBio
Tel: +32 2 739 11 83; Email: firstname.lastname@example.org
Communications Manager, EuropaBio
Tel: +32 2 739 11 84; Email: email@example.com